Group 1: Company Overview and Market Position - Hunan Jiudian Pharmaceutical Co., Ltd. has a complete industrial chain layout, enabling self-production of raw materials and key auxiliary materials, which helps control product quality and costs [2] - The company has achieved comprehensive channel coverage, including both hospital and outpatient markets, with the outpatient market becoming a new growth point [2] - Jiudian Pharmaceutical is focused on enhancing its "Jiuyue" transdermal patch brand to strengthen its influence in the transdermal drug delivery field [2][3] Group 2: Sales and Marketing Strategies - The company is actively expanding its outpatient market resources and has developed new sales strategies to enhance brand influence [3] - A multi-faceted approach to brand promotion includes integrating online and offline channels, collaborating with pharmacies, and establishing flagship stores on e-commerce platforms [3] - The company emphasizes patient education and academic promotion to enhance product recognition among healthcare professionals [3] Group 3: Product Development and Future Plans - The "Jiao Qi She" gel patch is currently undergoing supplementary research to meet the latest CDE clinical trial guidelines [3] - The Ketoprofen gel patch was approved for market entry in 2023 and has been included in the national medical insurance directory, with optimistic market prospects [3][4] - The company plans to focus on three key areas in its 2025 strategic planning: expanding sales channels, increasing R&D efforts, and optimizing production processes for cost control [4] Group 4: Market Trends and Consumer Insights - The sales channels for the anti-inflammatory and analgesic patch primarily target OTC channels, with strategies to enhance sales through resource sharing and product matrix expansion [4] - The aging population is expected to increase the chronic pain patient demographic, further driving demand for transdermal drug delivery products [4]

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转 02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2025-03 |  | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 其他 | | 参与单位名称及 | 华洲投资、兴业证券、国金证券、鑫巢资本、德福资本、招 | | 人员姓名 | 商资管、见素私募、思宝资管、文多资管、财信信托机构投 | | | 资者代表共 10 人 | | | 2025 年 2 月 11 日下午 2:00-3:00 | | 时间 | 2025 年 2 月 12 日上午 10:00-11:00 | | 地点 | 公司会议室 | | 上市公司接待人 | 副总经理兼董事会秘书：曾蕾 | | 员姓名 | 证券事务代表：甘荣 | | | 主要采用解答投资者提问的方式进行，主要问题回复如下： | | | 1、2025 年公司对院外市场的销售有怎样的目标？ | | | 回复：公司在持续强化院内销售的同时，正积极拓展院 | | ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-007 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于股东减持股份实施完毕的公告 股东段立新保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 湖南九典制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日披露 《关于股东减持股份的预披露公告》（公告编号：2024-072），公司持股 5%以上 股东段立新女士，计划以集中竞价交易或大宗交易方式减持本公司股份不超过 14,772,180 股（占本公司总股本比例 3%）。 近日，公司收到段立新女士出具的《股份减持计划实施进展告知函》，段立 新女士决定提前终止本次减持计划，未完成减持的股份在剩余减持计划期间内将 不再减持。现将相关情况公告如下： 一、股东的基本情况 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持时间 | | 减持均价（元/股） 减持股数（股） 减持比例（%） | ...

湖南九典制药股份有限公司（以下简称"公司"）于 2024 年 8 月 23 日召开 的第四届董事会第六次会议审议通过了《关于与专业投资机构共同投资暨关联交 易的议案》，同意公司使用自有资金，上限不超过 9,000 万元，与专业投资机构 及其他合伙人共同投资设立长沙湘江善诺创业投资合伙企业（有限合伙）（以下 简称"湘江善诺"）。湘江善诺已于 2024 年 11 月完成工商注册登记，并取得湖南 湘江新区管理委员会颁发的《营业执照》。 具体内容详见公司于 2024 年 8 月 24 日、2024 年 11 月 18 日在巨潮资讯网 披露的《关于与专业投资机构共同投资暨关联交易的公告》（公告编号：2024-058）、 《关于与专业投资机构共同投资暨关联交易的进展公告》（公告编号：2024-076）。 二、交易进展 近日，公司收到湘江善诺执行事务合伙人通知，湘江善诺已在中国证券投资 基金业协会完成基金备案。备案信息如下： | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-006 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-005 | 湖南九典制药股份有限公司 关于控股股东、实际控制人、董事长增持股份计划实施完成的公告 公司控股股东、实际控制人、董事长朱志宏先生保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、增持计划的基本情况：湖南九典制药股份有限公司（以下简称"公司"） 控股股东、实际控制人、董事长朱志宏先生计划自 2025 年 1 月 20 日起 6 个月内 以自有资金通过深圳证券交易所集中竞价交易的方式增持公司股份，拟增持总金 额不低于人民币 1,000 万元（含本数）且不超过 2,000 万元（含本数）。 2、增持计划的实施情况：2025 年 1 月 20 日至 1 月 21 日，朱志宏先生通过 深圳证券交易所以集中竞价交易方式累计增持 1,200,000 股，占公司总股本的 0.24%，增持总金额为 18,892,520 元， ...

Core Viewpoint - The company, Jiutian Pharmaceutical, announced that its controlling shareholder and chairman, Zhu Zhihong, plans to increase his stake in the company through the Shenzhen Stock Exchange within six months, with a total investment amount between 10 million and 20 million yuan [1] Group 1 - The controlling shareholder and actual controller of the company is Zhu Zhihong [1] - The planned share purchase will be conducted through centralized bidding on the Shenzhen Stock Exchange [1] - The total amount for the share buyback is set to be no less than 10 million yuan and no more than 20 million yuan [1]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-003 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于控股股东、实际控制人、董事长增持股份计划的公告 公司控股股东、实际控制人、董事长朱志宏先生保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 湖南九典制药股份有限公司（以下简称"公司"）控股股东、实际控制人、 董事长朱志宏先生计划自本公告披露日起 6 个月内以自有资金通过深圳证券交 易所系统采用集中竞价交易的方式增持公司股份，拟增持总金额不低于人民币 1,000 万元（含本数）且不超过 2,000 万元（含本数）。 增持计划实施的不确定风险：本次增持计划可能存在因资本市场情况发生变 化或目前尚无法预判的其他风险因素导致增持计划的实施无法达到预期的风险。 如增持计划实施过程中出现相关风险情形，公司将及时履行信息披露义务。 一、计划增持主体的基本情况 1、计划增持主体：公司控股股东、实际 ...

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转 02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2025-01 | |  特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 其他 | | 参与单位名称及 人员姓名 | 时间投资机构投资者代表共 1 人 | | 时间 | 2025 年 1 月 3 日上午 9:30-10:30 | | 地点 | 公司会议室 | | 上市公司接待人 | 副总经理兼董事会秘书：曾蕾 | | 员姓名 | 证券事务代表：甘荣 | | | 主要采用解答投资者提问的方式进行，主要问题回复如下： | | | 1、洛索洛芬钠凝胶贴膏的销售情况和经营趋势？ | | | 回复：洛索洛芬钠凝胶贴膏在院内、院外同步拓展上量， | | | 销售数量同比增长较快，经营趋势持续向好。 | | | 2、公司认为洛索洛芬钠凝胶贴膏单品在院外市场的空间有 | | 投资者关系活动 主要内容介绍 | 多大？ | | | 回复：根据摩熵医药的数 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-001 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于 2024 年第四季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 经中国证券监督管理委员会证监许可〔2023〕526 号文同意注册，公司于 2023 年 9 月 15 日向不特定对象发行了 360.00 万张可转债，每张面值 100 元，发行总 额为 36,000.00 万元。 经深圳证券交易所（以下简称"深交所"）同意，公司可转债于 2023 年 10 月 13 日起在深交所挂牌交易，债券简称：九典转 02，债券代码：123223。 根据《深圳证券交易所创业板股票上市规则》和《湖南九典制药股份有限公 司创业板向不特定对象发行可转换公司债券募集说明书》的规定，公司可转债的 转股期限自 2024 年 3 月 21 日起至 2029 年 9 月 14 日止。 二、可转债转股及股份变动情况 1、九典转02 ...

Summary of Conference Call Company and Industry Involved - The conference call primarily discusses the pharmaceutical industry, focusing on companies involved in drug development and clinical trials, particularly in the context of regulatory approvals and market competition. Key Points and Arguments 1. **Regulatory Concerns**: The market is primarily worried about two issues: the approval process for new drugs and the actions of competitors in submitting production applications. The recent submission by Wan Gao for production approval has raised concerns among investors [1][2][3]. 2. **Clinical Trial Updates**: Companies are actively engaging with the Center for Drug Evaluation (CDE) regarding their clinical trial submissions. There is a consensus that complex drug types require extensive clinical trials, and many companies are currently conducting these trials [4][6]. 3. **Market Dynamics**: The discussion highlights the competitive landscape, particularly regarding the introduction of generic drugs. Companies are preparing for potential competition from new entrants in the market, which could impact their sales [9][32]. 4. **Pricing Strategies**: The company emphasizes adherence to national pricing guidelines and the importance of maintaining reasonable distribution costs. This is crucial to avoid issues related to pricing regulations [7]. 5. **Future Growth Expectations**: The company anticipates significant growth in the outpatient market, with plans to expand its product offerings and marketing strategies. There is a target to double sales in the outpatient sector by 2025 [10][12]. 6. **Investment in R&D**: The company is committed to enhancing its research and development capabilities, with a focus on developing new products that can be quickly commercialized. This includes expanding its product line and improving production processes [16][17]. 7. **Clinical Trial Costs**: The estimated cost for conducting large-scale clinical trials is around 20 million, with additional investments required for facility upgrades and equipment [11]. 8. **Market Positioning**: The company believes it has a competitive advantage due to its established production capabilities and a comprehensive sales team across various channels, including hospitals and clinics [33][34]. Other Important but Possibly Overlooked Content 1. **Challenges in Consistency**: There are significant challenges in achieving consistency in drug formulations, particularly with complex ingredients. This has been a point of contention in regulatory discussions [14][15][27]. 2. **Regulatory Guidance**: The lack of clear regulatory guidelines from the CDE has created uncertainty in the approval process, leading to fluctuations in stock prices based on market speculation [25][26]. 3. **International Comparison**: The call discusses differences in regulatory approaches between China, the US, and Japan, particularly regarding the approval of topical medications and the requirements for demonstrating bioequivalence [21][22][30]. This summary encapsulates the critical discussions and insights shared during the conference call, providing a comprehensive overview of the company's current standing and future outlook in the pharmaceutical industry.